← daily scanner dashboard

#4 CORT — CORCEPT THERAPEUTICS INC

A2_VCP_NEAR_PIVOT | as of 2026-10-02 | automated relative priority, not a published Minervini point formula

Relative priority61.67
RS rating94.88
Fundamental strength66.67
VCP score87.30
Pivot distance1.37%
AV confirmation100.00%complete
Technical chart for CORT

Trend Template

price_above_sma150_and_sma200PASS
sma150_above_sma200PASS
sma200_rising_1mPASS
sma50_above_sma150_and_sma200PASS
price_above_sma50PASS
price_at_least_30pct_above_52w_lowPASS
price_within_25pct_of_52w_highPASS
rs_rating_at_least_70PASS

Trend Template metrics

close116.23
sma50113.00
sma15077.52
sma20069.92
sma200_1m_ago66.27
pct_above_52w_low305.55
pct_below_52w_high8.03
rs_rating94.88

VCP conditions

coherent_contraction_sequencePASS
enough_contractionsPASS
successive_ranges_inside_firstPASS
successive_depths_contractingPASS
final_contraction_tightPASS
base_depth_okPASS
resistance_area_tightPASS
volume_dryupPASS
atr_contractingFAIL
price_tightFAIL
near_pivotPASS

VCP metrics

num_contractions2.00
contraction_depths_pct[14.35, 8.0]
depth_ratios_vs_prior[0.557]
target_depth_ratio_roughly_half0.50
max_allowed_depth_ratio0.80
base_high126.38
base_low108.25
base_depth_pct14.35
base_duration_weeks5.40
resistance_spread_pct6.76
volume_dryup_ratio_10d_vs_50d0.71
atr_pct_recent4.76
atr_pct_prior4.47
atr_contraction_ratio1.07
tight_10d_range_pct10.56
raw_contraction_count8.00
raw_depths_pct[5.95, 7.79, 9.39, 10.76, 7.82, 12.18, 14.35, 8.0]
final_trough_age_bars10.00
selection_reasoncoherent_current_sequence
pivot_price117.84
distance_to_pivot_pct1.37
vcp_score_pct87.30
is_vcp_candidatePASS
breakout_on_volumeFAIL

Price / volume

return_1m_pct5.25
return_3m_pct26.87
return_6m_pct173.55
return_12m_pct37.96
weighted_12m_momentum26.55
range_10d_pct10.56
range_20d_pct11.33
avg_volume_50d1.35M
dollar_volume_50d156.53M
up_down_volume_ratio_50d0.61
accumulation_days_20d4.00
distribution_days_20d2.00

Fundamental overlay criteria

eps_growth_minimumPASS
sales_growth_positive_or_betterPASS
core_data_coveragePASS
eps_acceleratingPASS
sales_acceleratingPASS
gross_margin_improving—
operating_margin_improvingPASS

Minervini-oriented SEC fundamentals

eps_growth_yoy_pct24.14
eps_previous_q_yoy_growth_pct-276.47
eps_acceleration_pts300.61
eps_annual_growth_pct-33.33
eps_cagr_3y_pct-1.95
sales_growth_yoy_pct31.74
sales_previous_q_yoy_growth_pct4.89
sales_acceleration_pts26.85
sales_annual_growth_pct12.79
sales_cagr_3y_pct23.74
gross_margin_pct—
operating_margin_pct16.12
pretax_margin_pct17.93
net_margin_pct16.78
gross_margin_yoy_change_pts—
operating_margin_yoy_change_pts2.40
roe_latest_fy_pct15.02
current_ratio2.86
debt_to_equity_pct—
cash_to_debt—
shares_outstanding—
adjusted_eps_growth_yoy_pct—
earnings_surprise_pct—
eps_estimate_revision_30d_pct—
analyst_count—
institutional_ownership_pct—
institutional_qoq_change_pct—
management_guidance_revision_pct—

SEC data quality

core_coverage_pct90.00
missing_core_metrics["shares_outstanding"]
selected_sec_tags{"accounts_payable": "us-gaap:AccountsPayableCurrent", "accounts_receivable": "us-gaap:AccountsReceivableNetCurrent", "capex": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "cash": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "cost_of_revenue": "us-gaap:CostOfRevenue", "current_assets": "us-gaap:AssetsCurrent", "current_liabilities": "us-gaap:LiabilitiesCurrent", "dividends_paid": null, "eps_basic": "us-gaap:EarningsPerShareBasic", "eps_diluted": "us-gaap:EarningsPerShareDiluted", "equity": "us-gaap:StockholdersEquity", "gross_profit": "us-gaap:GrossProfit", "inventory": "us-gaap:InventoryNet", "long_term_debt": "us-gaap:LongTermDebtNoncurrent", "long_term_debt_current": "us-gaap:LongTermDebtCurrent", "net_income": "us-gaap:NetIncomeLoss", "operating_cash_flow": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "operating_income": "us-gaap:OperatingIncomeLoss", "pretax_income": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "r_and_d": "us-gaap:ResearchAndDevelopmentExpense", "revenue": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "sga": "us-gaap:SellingGeneralAndAdministrativeExpense", "share_repurchases": "us-gaap:PaymentsForRepurchaseOfCommonStock", "shares_outstanding": "dei:EntityCommonStockSharesOutstanding", "short_term_debt": null, "short_term_investments": "us-gaap:MarketableSecuritiesCurrent", "stock_based_comp": "us-gaap:ShareBasedCompensation", "total_assets": "us-gaap:Assets", "total_liabilities": "us-gaap:Liabilities", "weighted_avg_diluted_shares": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"}
unavailable_canonical_concepts["dividends_paid", "short_term_debt"]
warnings["Standalone Q4 income/EPS can be absent because 10-K statements are annual.", "Company-specific extension tags are not returned by CompanyFacts.", "Non-GAAP EPS, guidance, 13F ownership, Form 4 activity, and analyst estimates are separate modules."]

Reporting periods

latest_quarter_end2026-06-30
latest_quarter_filed2026-07-29
latest_fiscal_year_end2025-12-31
latest_balance_sheet_end2026-06-30

Company metadata

symbolCORT
cik1.09M
company_nameCORCEPT THERAPEUTICS INC
exchange—
sic2,834
sic_descriptionPharmaceutical Preparations
fiscal_year_end1,231
as_of2026-10-04
sourceSEC EDGAR CompanyFacts + Submissions

Alpha Vantage enrichment

latest_reported_date2026-07-29
latest_reported_eps0.36
latest_estimated_eps-0.04
latest_earnings_surprise_pct1,000
avg_earnings_surprise_4q_pct219.69
positive_earnings_surprises_4q2.00
earnings_surprise_quarters_available4.00
reported_eps_yoy_growth_pct24.14
estimate_period2027-12-31
analyst_count_eps—
analyst_count_revenue—
eps_estimate_avg—
revenue_estimate_avg—
estimate_revision.eps_estimate_revision_up_trailing_7_days2.00
estimate_revision.eps_estimate_revision_up_trailing_30_days2.00
estimate_revision.eps_estimate_revision_down_trailing_30_days0.00
eps_revision_up_30d2.00
eps_revision_down_30d0.00
eps_revision_net_up_30d2.00
institutional.total_institutional_holders493.00
institutional.total_institutional_shares92.42M
institutional.holders_with_increased_holdings283.00
institutional.holders_with_decreased_holdings171.00
institutional.holders_with_unchanged_holdings39.00
institutional_holder_rows493.00
institutional_total_shares92.42M
endpoints_returned["EARNINGS", "EARNINGS_ESTIMATES", "INSTITUTIONAL_HOLDINGS"]

Alpha Vantage confirmation screen

latest_earnings_surprise_positivePASS
average_4q_earnings_surprise_positivePASS
positive_surprise_quartersPASS
analyst_coverage_present—
eps_revision_breadth_nonnegative_30dPASS
institutional_sponsorship_presentPASS

Alpha Vantage screen summary

statuscomplete
confirmation_score_pct100.00
available_criteria5.00
noteInformational post-Exp0 confirmation only; not part of validated Exp0 selection/ranking.

Alpha Vantage endpoint status

EARNINGScache_available
EARNINGS_ESTIMATEScache_available
INSTITUTIONAL_HOLDINGScache_available

Accepted VCP contractions

peak_datepeak_pricetrough_datetrough_pricedepth_pctdepth_ratio_vs_priorbars
2026-08-25126.382026-09-08108.2514.35—9.00
2026-09-11117.842026-09-18108.418.000.565.00

Recent SEC filings

formfiling_dateaccession_numberprimary_document
8-K2026-09-230001193125-26-398561d148256d8k.htm
10-Q2026-07-290001628280-26-050613cort-20260630.htm
8-K2026-07-290001628280-26-050607cort-20260729.htm
8-K2026-06-170001193125-26-274258d159941d8k.htm
8-K2026-06-030001193125-26-254622d103585d8k.htm
8-K2026-05-280001628280-26-038793cort-20260521.htm
10-Q2026-04-300001628280-26-028902cort-20260331.htm
8-K2026-04-300001628280-26-028892cort-20260430.htm
8-K2026-03-250001193125-26-123543d123475d8k.htm
10-K2026-02-240001628280-26-011091cort-20251231.htm
8-K2026-02-240001628280-26-011080cort-20260224.htm
8-K2026-02-190001193125-26-059551d25779d8k.htm

SEPA factors not covered by SEC + Yahoo

These remain manual or require another provider/module and are deliberately not guessed: